Dr. Parsa on a Trial Analyzing G-200 for Glioblastoma

Andrew T. Parsa, MD, PhD
Published: Tuesday, Jul 02, 2013

Andrew T. Parsa MD, PhD, Associate Professor in Residence of Neurological Surgery, University of California, San Francisco, describes the design of a trial analyzing prophage G-200 vaccine for recurrent glioblastoma multiforme.

Prophage G-200 is an autologous, patient-specific vaccine used to provoke an immune response in patients with recurrent glioblastoma multiforme. This ongoing phase II study, sponsored by the Alliance for Clinical Trials in Oncology, a cooperative group of the National Cancer Institute, was designed so that patients who have recurrent glioblastoma undergo surgical resection and have confirmation of their diagnosis. Then, the resected tissue is converted into the vaccine, which is held by researchers.

Patients in the trial are randomized to one of three arms: bevacizumab alone, the current standard of care in this disease, bevacizumab in combination with the vaccine, or the vaccine followed by bevacizumab. The study looks to answer the question of whether prophage G-200 can facilitate long term overall survival.

Andrew T. Parsa MD, PhD, Associate Professor in Residence of Neurological Surgery, University of California, San Francisco, describes the design of a trial analyzing prophage G-200 vaccine for recurrent glioblastoma multiforme.

Prophage G-200 is an autologous, patient-specific vaccine used to provoke an immune response in patients with recurrent glioblastoma multiforme. This ongoing phase II study, sponsored by the Alliance for Clinical Trials in Oncology, a cooperative group of the National Cancer Institute, was designed so that patients who have recurrent glioblastoma undergo surgical resection and have confirmation of their diagnosis. Then, the resected tissue is converted into the vaccine, which is held by researchers.

Patients in the trial are randomized to one of three arms: bevacizumab alone, the current standard of care in this disease, bevacizumab in combination with the vaccine, or the vaccine followed by bevacizumab. The study looks to answer the question of whether prophage G-200 can facilitate long term overall survival.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x